Marcus Kline: Ben — I had a strange moment this week. My father's physician used the phrase 'doing well for his age,' and I started thinking: what does that actually mean as a clinical standard? Because apparently, 250 leaders in healthcare and pharma just sat in a room in Boston and decided it means nothing.
Ben Okonkwo: Wait — this is the WMIF panel, the Mass General Brigham forum?
Marcus Kline: September 22nd and 23rd, Boston, hosted by Mass General Brigham with Bank of America. The longevity panel was titled 'Toward a Model of Age, Aging and Therapeutic Rejuvenation.' And Kristen Fortney — she's the one who anchors it — she puts the US healthspan-lifespan gap at roughly 20 years. Two decades where people are technically alive but not, by any meaningful measure, well.
Ben Okonkwo: Okay, 20 years is doing a lot of work in that argument — where does that figure actually come from?
Marcus Kline: That's — and that's precisely the thread I want to pull. But set the sourcing aside for a moment, because the more immediate problem is this: the forum declared that medicine's success metric needs to shift from calendar survival to intrinsic capacity — cognition, mobility, sensory function, vitality, psychological capacity — and then the forum ended, and the FDA did not change one approval criterion. Not one primary endpoint standard for clinical trials. Not one insurance reimbursement category. Nothing in the regulatory structure that controls what actually gets developed and funded moved at all.
Ben Okonkwo: That's a genuine gap — I mean, intrinsic capacity isn't even a validated primary endpoint in most trial designs right now.
Marcus Kline: And yet there it is, presented to 250-plus leaders from pharma, biotech, venture capital, government — as the field's new north star. The words reorganized. The money, the trials, the approvals — none of it.
Ben Okonkwo: Right — but is that Mass General Brigham's failure, or is that just what 'leading' actually looks like before the infrastructure catches up?
Marcus Kline: That's actually the right frame for the number itself — because the infrastructure question waits on what the number is actually measuring. Think of a car that runs for twenty years, but the engine starts failing at year fifteen. The odometer still ticks. You're technically on the road. But you're not driving anymore. That's the gap Fortney is describing — not years lost to death, but years spent not really living.
Ben Okonkwo: Okay, that clicks. So — twenty years of not really driving.
Marcus Kline: Twenty years in the US, per Fortney at WMIF. Now the published analyses across 183 WHO member states put the mean gap at 9.6 years. Globally. And that is roughly half her figure.
Ben Okonkwo: Wait — so which number is Fortney actually using, and why didn't anyone on that panel flag that those are not the same conversation?
Marcus Kline: And that is — yes, that is exactly it. Because those two figures don't share a methodology. The global 9.6 uses one definition of healthspan. The US 20-year figure, the way Fortney deploys it, almost certainly draws from a different measurement frame — probably self-reported functional limitation data, not the same index. So the gap statistic is doing more narrative work than its methodology can actually support.
Ben Okonkwo: Right — but is that the GeroScience problem? Because that October 2026 paper, the one pushing back against the 'extend healthspan but not lifespan' framing as a cliché — that's the field catching itself doing exactly this.
Marcus Kline: It is. The field arguing with its own governing metaphor. In print.
Ben Okonkwo: So Fortney walks into a room at Mass General Brigham's forum, cites a figure that the broader literature would immediately complicate, and the 250 people in that room — pharma, biotech, venture capital — none of them asked where 20 years comes from?
Marcus Kline: None that made it into the record. And consider what that silence actually means — not that the number is wrong, necessarily, but that the room needed it to be load-bearing. The urgency deflates without a number that large.
Ben Okonkwo: But that's actually the structural crack, isn't it — because the room needing the number is exactly what happens when the measure you're advocating for isn't operational yet. Intrinsic capacity is five domains: mobility, cognition, sensory function, vitality, psychological capacity. The ICFSR Task Force sat down in March 2025 specifically to work through how geroscience trials should handle this. Aging biomarkers, senotherapeutics, metabolism-targeting interventions — all of it on the table. And intrinsic capacity is still supplementary.
Marcus Kline: Supplementary. Not primary.
Ben Okonkwo: Right — and that's the load-bearing distinction. Active pipeline does not equal primary endpoint. Those are different animals. Sohaib Imtiaz described intrinsic capacity as more domain-specific than biological age — okay, fine, I follow that. But domain-specific and FDA-submittable are not the same sentence.
Marcus Kline: Now hold that against a concrete case, because this is where the abstraction becomes — I mean, it becomes a person. Imagine a 74-year-old woman. She scores fine on every mortality-risk checklist. Standard trial endpoints count her as a success. But she can no longer carry groceries up her apartment stairs. She can't follow a conversation in a noisy room. The trial says: healthy. Intrinsic capacity says: she's already losing the things that make the years worth living.
Ben Okonkwo: And that scenario — that's not hypothetical, that's the design gap. Current regulatory criteria would have literally no mechanism to catch that.
Marcus Kline: None. And then GeroScience publishes — October 2026 — a paper explicitly calling 'extend healthspan but not lifespan' a cliché. The field's own governing metaphor. In print. That's not marginal dissent, that's the research community catching itself performing the answer rather than measuring it.
Ben Okonkwo: No, I don't buy that it's purely performance — wait, actually, that's not what I mean. The disagreement in that GeroScience paper is more specific. It's about whether the framing itself forecloses questions. If you've declared the goal is healthspan and not lifespan, you've already decided what success looks like before you've built the instrument to measure it.
Marcus Kline: Which is — yes. The instrument question is exactly where the ICFSR Task Force's March 2025 work should have landed some answers, and yet here we are, eight months later at WMIF, and intrinsic capacity is still decorative in trial design.
Ben Okonkwo: And the part that comes later makes this worse — because even if intrinsic capacity becomes the operative measure, who actually gets access to the tools that move those five domains? That's a different problem entirely.
Marcus Kline: The field solved the vocabulary. The infrastructure is still the unanswered question.
Ben Okonkwo: And that access question — that's where I think the whole frame starts to buckle. David Rehkopf at Stanford Medicine said it flat out: longevity is fundamentally a policy challenge, not a biological one. The Stanford Longevity Center framed it as institutional and structural. So if intrinsic capacity becomes the gold standard but the tools that measure it — genomic screening, AI-assisted biomarker tracking — are distributed by income and zip code, then we haven't closed a gap. We've just moved it somewhere harder to see.
Marcus Kline: Relocated the inequality.
Ben Okonkwo: Right — and the 2026 Frontiers in Medicine paper, the Macdonald piece, the one proposing Medicine 4.0 — it's actually explicit on this. Both the lifespan model and the healthspan model are incomplete without a third dimension: radical access to the tools themselves. The Paris Healthy Longevity Summit called for action grounded in WHO's healthy aging framework. The Lancet Healthy Longevity has been publishing on this since October 2020. But neither venue resolved who actually gets the intrinsic capacity workup.
Marcus Kline: And here's what I want to — I mean, the funding question is where this gets genuinely uncomfortable. The Saudi Hevolution Foundation is one of the largest single funders shaping the geroscience agenda right now. And when a foundation of that scale shapes which biological targets get prioritized, you have to ask: whose healthspan is the research actually designed around?
Ben Okonkwo: Wait — Hevolution is funding primary geroscience research?
Marcus Kline: Shaping the agenda. That's the documented claim. And that matters because the US National Institute on Aging spent decades building the geroscience infrastructure — the ICFSR Task Force, the trial frameworks — and now a private foundation with different stakeholder pressures is at the table. The priorities don't have to be identical.
Ben Okonkwo: Okay — so picture a rural cardiologist in, I don't know, eastern Kentucky. She wants to actually track a patient's intrinsic capacity across those five domains. Cognition, mobility, sensory function. She doesn't have the AI-assisted detection infrastructure. She doesn't have the biomarker pipeline. The framework says her patient matters. The tools say otherwise.
Marcus Kline: And that's — yes, that's the honest endpoint of the WMIF declaration. The vocabulary got more precise. The cardiologist's situation did not.
Ben Okonkwo: Rehkopf's point stands, then. The biology improved. The policy didn't move. And until housing, transportation, healthcare access — the actual co-determinants of whether someone's retained capacity translates to function — until those shift, the healthspan frame is doing something real scientifically and almost nothing structurally.
Marcus Kline: And that is — I think that's where I keep landing. Mass General Brigham convened 250 people on September 22nd. The US National Institute on Aging has been making this argument for years. The WHO's healthy aging framework. The 2026 Paris Summit's call to action. All of it pointing the same direction. So the question I genuinely cannot answer is: did anything actually change in Boston? Or did 'intrinsic capacity' just become the new vocabulary that old institutions reach for when they want to sound like they've moved?
Ben Okonkwo: I don't have a clean answer to that.
Marcus Kline: Neither do I. And I'm not sure the field does either.
